There was some intriguing news from a Pfizer (NYSE: PFE) shareholder on Thursday that was not taken well by the market.

GSK shares rose after the British drug major agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer. Write to Rob ...

Former Pfizer CEO Ian Read and former CFO Frank D’Amelio announced their withdrawal from Starboard Value’s activist campaign ...

As the battle over Pfizer’s future continues, former executives said they would no longer support activist investor Starboard ...

Hedge fund Starboard Value's activist campaign targeting Pfizer (PFE) divides Wall Street, with analysts questioning the ...

Two former Pfizer executives published a statement saying they support the current company management as it gets pressured ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current CEO ...

On Thursday, Starboard Value LP, a significant shareholder of Pfizer Inc. (NYSE:PFE), issued a letter to the company’s Board ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Two former Pfizer top executives won’t participate in an activist investor’s effort to pressure the drugmaker to make changes ...

In a letter to Pfizer’s board, the activist investor claimed former CEO Ian Read and CFO Frank D’Amelio were pressured to abandon a Starboard-led attempt to change the company’s direction.

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...